Adicet Bio Past Earnings Performance
Past criteria checks 0/6
Adicet Bio's earnings have been declining at an average annual rate of -34.8%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been declining at an average rate of 14.9% per year.
Key information
-34.8%
Earnings growth rate
30.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -14.9% |
| Return on equity | -55.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?
Jul 12
Adicet Bio: Microcap With A High Risk To Reward Ratio
May 23Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate
Feb 01Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth?
Dec 07Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?
Aug 07Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans
Apr 20Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation
Dec 20Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio
Oct 17Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?
Oct 04Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term
Aug 16Adicet Bio: A First Take
Jul 22Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans
Jul 07Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit
May 15We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate
Mar 18Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate
Feb 09Revenue & Expenses Breakdown
How Adicet Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -118 | 28 | 101 |
| 30 Jun 24 | 0 | -137 | 27 | 101 |
| 31 Mar 24 | 0 | -140 | 27 | 103 |
| 31 Dec 23 | 0 | -143 | 27 | 106 |
| 30 Sep 23 | 0 | -143 | 26 | 106 |
| 30 Jun 23 | 0 | -115 | 26 | 97 |
| 31 Mar 23 | 0 | -105 | 26 | 85 |
| 31 Dec 22 | 25 | -70 | 26 | 71 |
| 30 Sep 22 | 30 | -56 | 26 | 61 |
| 30 Jun 22 | 34 | -48 | 25 | 56 |
| 31 Mar 22 | 39 | -36 | 23 | 50 |
| 31 Dec 21 | 10 | -62 | 22 | 48 |
| 30 Sep 21 | 10 | -55 | 14 | 42 |
| 30 Jun 21 | 9 | -56 | 16 | 39 |
| 31 Mar 21 | 12 | -54 | 19 | 38 |
| 31 Dec 20 | 18 | -37 | 16 | 34 |
| 30 Sep 20 | 14 | -34 | 20 | 31 |
| 30 Jun 20 | 4 | -34 | 14 | 29 |
| 31 Mar 20 | 0 | -28 | 9 | 26 |
| 31 Dec 19 | 1 | -28 | 9 | 24 |
| 31 Dec 18 | 8 | -9 | 8 | 15 |
Quality Earnings: ACET is currently unprofitable.
Growing Profit Margin: ACET is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACET is unprofitable, and losses have increased over the past 5 years at a rate of 34.8% per year.
Accelerating Growth: Unable to compare ACET's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACET is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ACET has a negative Return on Equity (-55.73%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 02:41 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Adicet Bio, Inc. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Zelin | B. Riley Securities, Inc. |
| John Newman | Canaccord Genuity |
| Yatin Suneja | Guggenheim Securities, LLC |